TRESIBA is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus (1).

Limitations of Use:
Not recommended for treating diabetic ketoacidosis.
DOSAGE AND ADMINISTRATION

•

Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoring results and glycemic control goal ( 2.1, 2.2, 2.3, 2.4).

•

Rotate injection sites to reduce the risk of lipodystrophy ( 2.1).

•

Do not dilute or mix with any other insulin or solution ( 2.1).

•

Administer subcutaneously once daily at any time of day ( 2.2).

•

Do NOT perform dose conversion when using the TRESIBA U-100 or U-200 FlexTouch pens. The TRESIBA U-100 and U-200 FlexTouch pens dose window shows the number of insulin units to be delivered and NO conversion is needed ( 2.2).

TRESIBA is available in the following package sizes:

•

100 units/mL (U-100): 3 mL FlexTouch ® ( 3).

•

200 units/mL (U-200): 3 mL FlexTouch ® ( 3).

•

During episodes of hypoglycemia ( 4).

•

Hypersensitivity to TRESIBA or one of its excipients ( 4).

WARNINGS AND PRECAUTIONS

•

Never share a TRESIBA FlexTouch pen between patients, even if the needle is changed ( 5.1).

•

Hyper- or hypoglycemia with changes in insulin regimen: Carry out under close medical supervision and increase frequency of blood glucose monitoring ( 5.2).

•

Hypoglycemia: May be life-threatening. Increase monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness (